STING Agonist‐Modified Tumor Targeting Photosensitizer Remodels Cancer‐Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer
Advanced Science · 2026-03 · 13 (13)
DOI: 10.1002/advs.202520547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.12.2025. Verfasst von Yixuan Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cancer-Associated Fibroblasts, Photosensitizing Agents, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Science and Technology Talents Lifting Project of Jiangsu Association for Science and Technology, Outstanding Young Scientist Fund of the Nanjing Health Science and Technology Development Program.
Abstract (Originalsprache)
Pancreatic cancer (PC) features dense stromal barriers and profound immune exclusion, rendering it largely unresponsive to immunotherapy. Here, we present ICyM2, a carrier‐free and esterase‐responsive nanoaggregate rationally designed by covalently linking the mitochondria‐targeting photosensitizer ICyOH with the non‐nucleotide STING agonist MSA‐2. This single‐molecule construct enables high drug loading, uniform nanoaggregate formation, and preferential tumor accumulation, thereby minimizing hepatic off‐target toxicity while allowing spatiotemporally controlled activation in the tumor microenvironment. Upon intratumoral activation, ICyOH disrupts cancer‐associated fibroblast (CAF)–mediated stromal barriers and triggers immunogenic cell death (ICD), which facilitates deep penetration of MSA‐2. Subsequently, MSA‐2 amplifies ICD‐derived antigenic signaling, activates the STING pathway, promotes dendritic cell maturation, reprograms macrophages toward an M1‐like phenotype, and enhances cytotoxic T‐cell infiltration. In vivo, ICyM2 elicits potent tumor regression, establishes durable immune memory that suppresses lung metastasis, and converts immunologically “cold” tumors into “hot.” Moreover, ICyM2 synergizes with PD‐1 blockade to further strengthen antitumor immunity without observable systemic toxicity. Collectively, ICyM2 integrates stromal remodeling and immune activation within a single, carrier‐free platform, providing a clinically translatable photo‐immunotherapeutic strategy to overcome stromal and immune resistance in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), ChemBioMed Interdisciplinary Research Center, Nanjing University, Nanj…
- Center of Hepatobiliary Pancreatic Disease, Xuzhou Central Hospital, Southeast University, Xuzhou, China.
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Förderung
- National Natural Science Foundation of China
- Young Science and Technology Talents Lifting Project of Jiangsu Association for Science and Technology
- Outstanding Young Scientist Fund of the Nanjing Health Science and Technology Development Program
- Clinical Trials from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
- Key Program of Nanjing Commission of Health
Zitieren
APA
Zhang, Y., Yao, S., Zhao, Y., Zhu, S., Fang, W., Yu, R., Shi, N., Zhang, R., Zhang, Y., Liang, J., Zhang, Z., Xu, S., Zhang, Z., Zhang, J., Li, Y., Han, X., Chen, Y., Zhang, S., & Lv, Y. (2026). STING Agonist‐Modified Tumor Targeting Photosensitizer Remodels Cancer‐Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer. Advanced Science, 13(13). https://doi.org/10.1002/advs.202520547
Vancouver
Zhang Y, Yao S, Zhao Y, Zhu S, Fang W, Yu R, et al. STING Agonist‐Modified Tumor Targeting Photosensitizer Remodels Cancer‐Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer. Advanced Science. 2026;13(13). doi:10.1002/advs.202520547
BibTeX
@article{Zhang2026,
author = {Zhang, Yixuan and Yao, Shankun and Zhao, Yihan and Zhu, Saisai and Fang, Wen and Yu, Ranran and Shi, Naiwen and Zhang, Ruixin and Zhang, Yin and Liang, Jiawei and Zhang, Ziying and Xu, Shijin and Zhang, Ziwei and Zhang, Jiajun and Li, Yukun and Han, Xiaoxuan and Chen, Yuncong and Zhang, Shu and Lv, Ying},
title = {STING Agonist‐Modified Tumor Targeting Photosensitizer Remodels Cancer‐Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {13},
doi = {10.1002/advs.202520547}
}
EUVIMED